Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

112
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

NETosis associates with human TB lung tissue destruction and disease pathogenesis.

EMBO molecular medicine·2026
Same author

Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.

EJNMMI physics·2026
Same author

Corrigendum to <Advances in Dosimetry and Imaging for <sup>203</sup>Pb and <sup>212</sup>Pb Radiotheranostics'> <[Semin NuclMed55:1011-1031/https://doi.org/10.1053/j.semnuclmed.2025.09.006]>.

Seminars in nuclear medicine·2026
Same author

Imaging of infection in Nephro-urology: A practical nuclear medicine-focused review.

Seminars in nuclear medicine·2026

Related Experiment Video

Updated: Jun 28, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K

Advances in PSMA Alpha Theragnostics.

Mariza Vorster1, Mike Sathekge2

  • 1Department of Nuclear Medicine at Inkosi Albert Luthuli Hospital, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.

Seminars in Nuclear Medicine
|April 24, 2024
PubMed
Summary

Targeted alpha therapy with 225Ac-PSMA shows promise for prostate cancer, offering improved outcomes and overcoming resistance. Further research is needed to optimize patient selection, dosing, and side effect management for this advanced treatment.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

170

Related Experiment Videos

Last Updated: Jun 28, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

170

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiotherapy

Background:

  • Targeted alpha therapy (TAT) presents a novel therapeutic approach.
  • 225Ac-PSMA has emerged as a leading agent in alpha theranostics for prostate cancer.
  • Previous reviews relied on limited data; recent evidence offers a more robust understanding.

Purpose of the Study:

  • To provide an updated overview of 225Ac-PSMA in prostate cancer.
  • To synthesize findings from recent meta-analyses and multi-center studies.
  • To explore the broader application of TAT beyond end-stage treatment.

Main Methods:

  • Review of recent meta-analyses and multi-center retrospective studies.
  • Synthesis of emerging data on 225Ac-PSMA efficacy and safety.
  • Exploration of clinical trial data and case reports.

Main Results:

  • 225Ac-PSMA demonstrates potential in overcoming radiation resistance and inducing DNA damage.
  • Recent studies confirm the safety and efficacy of 225Ac-PSMA in prostate cancer patients.
  • Emerging evidence supports considering TAT earlier in the disease course.

Conclusions:

  • 225Ac-PSMA is a promising targeted alpha therapy for prostate cancer.
  • Key clinical challenges include patient selection, optimal dosing, and managing side effects like xerostomia.
  • Further research is essential to refine treatment protocols and maximize clinical benefit.